Audit Report Tv)
Report No: 0713308726
Version 1

Product Service

2.5.3 Measurement, Analysis, and Improvement, CAPA and Internal Audit

Subsystem Measurement, Analysis, and Improvement - CAPA and Internal Audit
Audit trail Martin Szepannek / Gabriele Mousset / Honorata Donnermair
records of
Area(s) visited Location# 10578
(location, e.g., For more details related to audit location and time refer to chapter 2.2 of this report.
site visited)

Audit criteria
according to
audit plan

"Measurement, Analysis and Improvement: Procedures for Measurement, Analysis, and Improvement of QMS Effectiveness and Product Conformity (MDSAP
Chapter 3, Task 1, Site: 10578);

(DIN)(EN) ISO 13485 - 4.2.1, 8.1, 8.2.1, 8.2.6, 8.5 + (DIN)(EN) ISO 9001 - 7.5.1, 8.5.5, 8.6, 9.1.1, 9.1.2, 10 + MDSAP - Australia - TG(MD)R Sch3 P1
1.4(3)(a),(b), (5)(b)(ii), (f) + MDSAP - Brazil - RDC ANVISA 16/2013: 5.3.1, 7.1, 7.2 + MDSAP - Japan - MO169: 6, 54, 55-1, 58, 59, 62, 63, 64; [Old: 6, 54, 55,
58, 59, 62, 63, 64] + MDSAP - USA - 21 CFR 820.100(a) + MDR - Article 10.9 13 ( m); Annex IX 2.2 [2 (b2, e); Annex XI 13 + MDD - Annex II (3.2)"
"Measurement, Analysis and Improvement: Sources of Quality Data (MDSAP Chapter 3, Task 2, Site: 10578);

(DIN)(EN) ISO 13485 - 7.5.4, 8.1, 8.2.1, 8.2.6, 8.4 + (DIN)(EN) ISO 9001 - 8.5.5, 8.6, 9.1.1, 9.1.2, 9.1.3 + MDSAP - Australia - TG(MD)R Sch3 P1 1.4(3)(a),(b),
(5)(b){iii), (f) + MDSAP - Brazil - RDC ANVISA 16/2013: 7.1.1.1, 9.1 + MDSAP - Japan - M0169: 43, 54, 55-1, 58, 59, 61; [Old: 43, 54, 55, 58, 59, 61] + MDSAP
- USA - 21 CFR 820.100(a) + MDR - Article 10.9 3 (m); Annex IX 2.2 (b); Article 88 + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)"

"Measurement, Analysis and Improvement: Investigation of Nonconformity (MDSAP Chapter 3, Task 3, Site: 10578);

(DIN)(EN) ISO 13485 - 8.5.2 + (DIN)(EN) ISO 9001 - 10.2 + MDSAP - Australia - TG(MD)R Sch3 P1 1.4(3)(a),(b), (5)(b)(iii),(f), TG(MD)R Sch1 P12 + MDSAP
- Brazil - RDC ANVISA 16/2013: 2.4, 6.5.1, 7.1.1.2 + MDSAP - Japan - MO169: 63 + MDSAP - USA - 21 CFR 820.100 (a)(2) + MDR- Article 10.9 [3 (I) + MDD
- Annex II (3.2), Annex V (3.2), Annex VI (3.2)"

"Measurement, Analysis and Improvement: Investigation of Potential Nonconformity (MDSAP Chapter 3, Task 4, Site: 10578);

(DIN)(EN) ISO 13485 - 8.5.3 + (DIN)(EN) ISO 9001 - 0.3.3, 6.1, 10.1, 10.3 + MDSAP - Australia - TG(MD)R Sch3 P1 1.4(3)(a),(b), (5)(b)(ili),(f), TG(MD)R Sch1
P1 2+ MDSAP - Brazil - RDC ANVISA 16/2013: 2.4, 7.1.1.1 + MDSAP - Japan - MO169: 64 + MDSAP - USA - 21 CFR 820.100(a)(2) ++ MDR - Article 10.9 3
(I) + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)"

"Measurement, Analysis and Improvement: Correction, Corrective Action, and Preventive Action (MDSAP Chapter 3, Task 5, Site: 10578);

(DIN)(EN) ISO 13485 - 8.2.1, 8.2.5, 8.3.1, 8.5.2, 8.5.3 + (DIN)(EN) ISO 9001 - 0.3.3, 6.1, 8.5.5, 9.1.1, 9.1.2, 10.1, 10.2, 10.3 + MDSAP - Australia - TG(MD)R
Sch1 P12, TG(MD)R Sch3 P1 1.4(3)(a),(b), (5)(b)(ii), (f)_ + MDSAP - Brazil - RDC ANVISA 16/2013: 2.4, 6.5, 7.1.1.3, 7.1.1.4, 7.1.1.5 + MDSAP - Japan -
MO169: 55-1, 57, 60-1, 63, 64; [Old: 55, 57, 60, 63, 64] + MDSAP - USA - 21 CFR 820.100(a)(3), 820.100 (a)(4),820.100(a)(6), 820.100(b) + MDR - Article
10.9 713 (I) + MDD - Annex Il (3.2), Annex V (3.2), Annex VI (3.2)"

"Measurement, Analysis and Improvement: Assessment of Design Change Resulting from Corrective or Preventive Action (MDSAP Chapter 3, Task 6, Site:
10578);

(DIN)(EN) ISO 13485 - 7.1, 7.3.9 + (DIN)(EN) ISO 9001 - 8.1, 8.3.6, 8.5.6 + MDSAP - Australia - TG(MD)R Sch1 P1 2 + MDSAP - Brazil - RDC ANVISA
16/2013: 2.4, 4.1.10 +MDSAP - Japan - M0169: 26, 36-1; [Old: 26, 36] + MDSAP - USA - 21 CFR 820.30(i), 820.30(g) + MDR - Article 10.9 11 s2, 10.9913
(a); Annex IX 2.2 §i2 (c1, c8) + MDD - Annex 11(3.2)"

"Measurement, Analysis and Improvement: Assessment of Process Change Resulting from Corrective or Preventive Action (MDSAP Chapter 3, Task 7, Site:
10578);

(DIN)(EN) ISO 13485 - 4.1.2, 4.1.4, 4.1.6, 4.2.1, 7.1, 7.5.2, 7.5.6, 7.5.7 + (DIN)(EN) ISO 9001 - 4.4, 7.5.1, 8.1, 8.4, 8.5.1 + MDSAP - Australia - TG(MD)R Sch1
P1 2; Sch3 P1 1.5(4); TG(MD)R Sch3 P1 1.5(2) + MDSAP - Brazil - RDC ANVISA 16/2013: 2.4, 5.6, 7.1.1.4 + MDSAP - Canada - CMDR 1, 34 + MDSAP -
Japan - MO169: 5-2, 5-4, 5-6, 6, 26, 29, 41, 45, 46; [Old: 5, 6, 26, 41, 45, 46] + MDSAP - USA - 21 CFR 820.100(a)(4), 820.100(a)(5), 820.70(b), 820.75(c) +
MDR - Annex IX 2.2 [2 (d); Annex XI 6.2 2, 12 + MDD - No specific requirements"

"Measurement, Analysis and Improvement: Identification and Control of Nonconforming Product (MDSAP Chapter 3, Task 8, Site: 10578);

(DIN)(EN) ISO 13485 - 8.3.1, 8.3.2 + (DIN)(EN) ISO 9001 - 8.7, 10.2 + MDSAP - Australia - TG(MD)R Sch3 P1 1.4(5)(b)(ii) ++ MDSAP - Brazil - RDC ANVISA
16/2013: 6.5, 7.1.1.6 +MDSAP - Japan - MO169: 60-1, 60-2; [Old: 60] + MDSAP - USA - 21CFR 820.90(a) + MDR - Annex IX 2.2 [2 (b2); Annex XI 6.2 [2,
1271"

"Measurement, Analysis and Improvement: Action Regarding Nonconforming Product Detected After Delivery (MDSAP Chapter 3, Task 9, Site: 10578);
(DIN)(EN) ISO 13485 - 8.3.3, 8.5.2 + (DIN)(EN) ISO 9001 - 8.7, 10.2 + MDSAP - Australia - TG(MD)R Sch1 P1 2, TG(MD)R Sch3 P1 1.4(3)(a),(b), (5)(b)iii),
(f) + MDSAP - Brazil - RDC ANVISA 16/2013: 2.4, 7.1.1.8 + MDSAP - Japan - MO169: 60-3, 63; [Old: 60, 63] + MDSAP - USA - 21 CFR 820.100(a) + MDR -
Article 10.9 93 (k), 10.12; Article 87-92 + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)"

"Measurement, Analysis and Improvement: Internal Audit (MDSAP Chapter 3, Task 10, Site: 10578);

(DIN)(EN) ISO 13485 - 6.2, 8.2.4 + (DIN)(EN) ISO 9001 - 7.2, 7.3, 9.2 + MDSAP - Australia - TG(MD)R Sch P11 1.4(5)(b)(ii) + MDSAP - Brazil - RDC ANVISA
16/2013: 7.3 + MDSAP - Japan - MO169: 22, 23,56 + MDSAP - USA - 21 CFR 820.22, 820.100 + MDR - Annex IX 2.2 [2 (b2); Annex XI 6.2 2 + MDD -
Annex II (3.2), Annex V (3.2), Annex VI (3.2)"

"Measurement, Analysis and Improvement: Information Supplied for Management Review (MDSAP Chapter 3, Task 11, Site: 10578);

(DIN)(EN) ISO 13485 - 5.6.2 + (DIN)(EN) ISO 9001 - 9.3.1 + MDSAP - Australia - TG(MD)R Sch3 P1 1.4(5)(b)(iii) + MDSAP - Brazil - RDC ANVISA 16/2013:
2.2.6, 7.1.1.7 + MDSAP - Japan - MO169: 19 + MDSAP - USA - 21 CFR 820.100 (a)(7) + MDR - Article 10.9 1. S2; Annex IX 2.2 [2 (c8)"

"Measurement, Analysis and Improvement: Evaluation of Information from Post-Production Phase, Including Complaints (MDSAP Chapter 3, Task 12, Site:
10578);

(DIN)(EN) ISO 13485 - 4.2.1, 7.2.3, 7.5.4 (a), 8.2.1, 8.2.2, 8.5.1 + (DIN)(EN) ISO 9001 - 7.5.1, 8.2.1, 8.5.5, 9.1.2, 10.1, 10.3 + MDSAP - Australia - TG(MD)R
Sch1 P1 2, Sch3 P1 1.4(3), 1.4(5)(b)(ili) &1.4(5)(f) + MDSAP - Brazil - RDC ANVISA 16/2013: 7.2 + MDSAP - Canada - CMDR 57-58 + MDSAP - Japan - M0169:
6, 29, 43, 55-1, 55-2, 62; [Old: 6, 29, 43, 55, 62] + MDSAP - USA - 21 CFR 820.198 + MDR - Article 10.9 {3 (i), 10.10; Annex IX 2.1 @@, 2.2 92 (b2);
Annex XI6.2 2; Article 83 - 86 + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)"

"Measurement, Analysis and Improvement: Communications with External Parties Involved on Complaints (MDSAP Chapter 3, Task 13, Site: 10578);
(DIN)(EN) ISO 13485 - 4.1.5, 7.4.1, 8.3.1 + (DIN)(EN) ISO 9001 - 4.4, 8.4, 10.2 + MDSAP - Brazil - RDC ANVISA 16/2013: 7.1.1.6 + MDSAP - Japan - M0169:
5-5, 37, 60-1; [Old: 5, 37, 60] + MDSAP - USA - 21 CFR 820.100(a)(6) + MDR - Annex IX 2.2 [2 (b2); Annex XI 6.2 §[2, 12 1 + MDD - Article 10”
"Measurement, Analysis and Improvement: Evaluation of Complaints for Adverse Event Reporting (MDSAP Chapter 3, Task 14, Site: 10578);

(DIN)(EN) ISO 13485 - 4.2.1, 7.2.3, 8.2.3 + (DIN)(EN) ISO 9001 - 4.4, 8.2.1, 8.4, 8.5.5 + MDSAP - Australia - TG(MD)R Sch3 P1 1.4(3)(c) + MDSAP - Brazil -
RDC ANVISA 16/2013: 7.1.1.8, RDC ANVISA 67/2009 + MDSAP - Canada - CMDR 59-61.1 + MDSAP - Japan - M0169: 6, 29, 55-3; [Old; 6, 29, 62] + MDSAP
- USA - 21 CFR 803 + MDR - Article 10.9 ]3(k), 10.12, 10.13; Article 80, 87, 88, 89, 94 + MDD - Article 10"

"Measurement, Analysis and Improvement: Evaluation of Quality Problems for Advisory Notices (MDSAP Chapter 3, Task 15, Site: 10578);

(DIN)(EN) ISO 13485 - 4.2.1, 7.2.3, 8.3.3 + (DIN)(EN) ISO 9001 - 4.4, 8.2.1, 8.4, 8.7 + MDSAP - Australia - TG(MD)R Sch3 P1 1.4(3)(c) + MDSAP - Brazil -
RDC ANVISA 16/2013: 7.1.1.8, RDC ANVISA 23/2012 + MDSAP - Canada - CMDR 63-65.1 + MDSAP - Japan - M0169: 6, 29, 60-3; [Old: 6, 29, 60] + MDSAP
- USA - 21 CFR 806, 820.100(a) + MDR - Article 10.9 3 (k), 10.12; Article 80, 87, 88, 89, 94 + MDD - Article 10”

"Measurement, Analysis and Improvement: Top Management Commitment to Measurement, Analysis, and Improvement Process (MDSAP Chapter 3, Task 16,
Site: 10578);

(DIN)(EN) ISO 13485 - 4.1.3, 5.2, 8.1, 8.5.1 + (DIN)(EN) ISO 9001 - 4.4, 5.1.2, 8.4, 9.1.1, 10.1, 10.3 + MDSAP - Brazil - RDC ANVISA 16/2013: 2.2.1 +
MDSAP - Japan - M0169: 5-3, 11, 54, 62; [Old: 5, 11, 54, 62] + MDR - Article 10.9 [3 (c) + MDD - Annex Il (2, 3.1)"

Brief description
of processes or
activities
evaluated to
demonstrate
what was
audited related
to the listed key
QMS documents
and records
reviewed below
considering
inputs, outputs,
and measures

ID: 31505

MAI 1 - Procedures for measurement, analysis and improvement (GM) 8.1;8.2.1; 8.2.6; 8.5 => Focus on System
Affected roles: Requester/Responsible Person/ CAPA Reviewer/CAPA Owner

The process DEMF PQ3300 describes the evaluation of system CAPA’s

CAPA triggers are e.g. audits/feedback/issues/proposals/complaints/data-analysis.

Requester and Responsible person have to make an immediate decision whether direct measures would be
necessary. The quality manager will be responsible for further investigation steps and for the CAPA decision. The
issue can be followed as “documented action” or as full CAPA. The documentation from here will be in Track Wise.
Main CAPA triggers: Major NC’s from audit/issue with effect on efficacy of system and increase of risk for health or
environment or missing process descriptions or external requirements.

Each case will be evaluated regarding risk within the risk form: PQ3300 — A01 Risk evaluation template. Following
aspects will be evaluated: Environment, Employees, Health of patients or users, integrated Managemensystem
/certification, and product conformity. If there is any risk identified a description and evaluation of the situation have to
be documented. Based on this evaluation the decision for further processing “CAPA” or documented action “ will be
done.

For each CAPA (not for “documented action”) a CAPA plan should be provided and the CAPA plan have to be checked
and approved by CAPA reviewer. The CAPA reviewer will take the decision whether the planned actions are
appropriate to the risk.

Doc No: MED_T_09.50 Revision: 12 — released Effective: 28 May 2021 Page 17 of 107
